10x Genomics Acquires Epinomics | GenomeWeb https://t.co/rq5BNEvQ0O

3:24pm August 28th 2018 via Hootsuite Inc.

Illumina Secures China National Drug Administration Clearance for MiSeqDx System | GenomeWeb https://t.co/fqUVN2ICis

2:44pm August 28th 2018 via Hootsuite Inc.

Available now: Pillar @Pillar_Bio's poster "Development and Evaluation of a Lung Cancer Fusion RNA Panel" from… https://t.co/RfM8AGerIZ

10:57am August 27th 2018 via Twitter Web Client

A CRISPR cure for Duchenne muscular dystrophy is closer after a trial in dogs - MIT Technology Review https://t.co/0vM9fV7qSa

6:55am August 27th 2018 via Hootsuite Inc.

Akonni Biosystems Scores $3M NIH Grant for POC Dx Platform, Drug-Resistant TB Assay | GenomeWeb https://t.co/lU4fbBEVKK

10:05am August 24th 2018 via Hootsuite Inc.

Haim #NGSDx18 The walls between gov't org's, gov't funding and VC's are breaking down.

12:44pm August 23rd 2018 via Twitter Web Client

DeWinter #NGDx18 Plenty of different kinds of risk, new models of reimbursement just adds another layer, so thus no innovation there.

12:38pm August 23rd 2018 via Twitter Web Client

Merkeley #NGDx18 To solve sepsis, they see themselves as partners with Medicare/Medicaid - coordinating with CMS/CDC and industry

12:29pm August 23rd 2018 via Twitter Web Client

DeWinter #NGDx18 Does it make sense to accept money from GE? The investment Q to answer.

12:26pm August 23rd 2018 via Twitter Web Client

DeWinter #NGDx18 No large exits (exception - ExosomeDx did north of $500M). Corporate VC: homework: where they are… https://t.co/cy1PPA6zFk

12:23pm August 23rd 2018 via Twitter Web Client

Alex DeWinter (GE Ventures) #NGDx18 Everything but drugs and implants. Clinical data analytics. For Dx: health economics looked at 1st.

12:22pm August 23rd 2018 via Twitter Web Client

Merkeley #NGDx18 They ask 'why has the market failed' and look for unique ways to partner, remove barriers etc.

12:18pm August 23rd 2018 via Twitter Web Client

Merkeley #NGDx18 Also dual-utility: sepsis affects 2M /year. Constantly look for opps to invest in. 12y: 38 FDA-app… https://t.co/6AoCrEvJu4

12:17pm August 23rd 2018 via Twitter Web Client

Merkeley #NGDx18 $1.5B budget; Congress recognizes that no one would develop products for an emergent threat (i.e. Anthrax)

12:16pm August 23rd 2018 via Twitter Web Client

Tyler Merkeley (BARDA) #NGDx18 $22M awarded for home flu tests. Teamed up with J&J for respiratory devices.

12:15pm August 23rd 2018 via Twitter Web Client

Haim #NGDx18 Majority emphasis on diagnostics side; October cycle; offer a lot of training opportunities as well

12:14pm August 23rd 2018 via Twitter Web Client

Haim #NGDx18 Want to talk, happy to engage pre-application; https://t.co/bP2vqz9FAd In Dx: conscious of commercial hurdles.

12:12pm August 23rd 2018 via Twitter Web Client

Haim #NGDx18 Can be much larger in later stages (up to $10M total); active in Cancer Moonshot, Opioid alternatives

12:11pm August 23rd 2018 via Twitter Web Client

Todd Haim (NCI SBIR) #NGDx18 Want to bring co's to next level of valuation, now more flexible. $300K or more, pre-clinical Stg I

12:10pm August 23rd 2018 via Twitter Web Client

Meuleman #NGDx18 $230M fund, lack of VCs who understood what it took to bring genomic tests to market. Also tools, dx not genomics-spec

12:09pm August 23rd 2018 via Twitter Web Client

Quinn #NGDx18 Investor in diagnostics: they face risk, skepticism, concerns. Panel: Wouter Meuleman (Ilumina Ventur… https://t.co/WENIxkFKFF

12:07pm August 23rd 2018 via Twitter Web Client

Next panel up at #NGDx18 Changing approaches to sustainable funding in diagnostics Moderator: Bruce Quinn (Bruce Quinn Assoc)

12:04pm August 23rd 2018 via Twitter Web Client

Tsongalis #NGDx18 Have been asking this question for 20y: how can the molecular lab add value to the pathologist?

11:59am August 23rd 2018 via Twitter Web Client

Q: Physicians' exposure vs this audience's exposure to NGS? #NGDx18 Icenhour: They train physicians 'every day'.

11:58am August 23rd 2018 via Twitter Web Client

Tsongalis #NGDx18 The consumer will have a lot more influence in the future!

11:57am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 Which of these data points actually help pts that we deal with? Tsongalis: Has two early-20's children, 'health-crazy'

11:56am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 We now have power to discover, and thus go back to the broad look. Scholz: 'When information increases wisdom declines'

11:55am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 Microbiome - 6 lbs/person of microbes, how does it affect behavior? Autism-like syndrome - could it be fungal inf? (!)

11:54am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 Push for POCT - but we are going all the way back, to get a broad look. 'Just because you can doesn't mean you should'

11:53am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 Predicts at least 1/2 'autoimmune' disorders are actually infections or microbiome-related (!)

11:53am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 One option: collection of blood spots over time? Then test when longitudinal data is needed. A retrospective study

11:52am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 Regular monitoring of tests: cost is still a barrier. Collecting info even though it isn't needed. But needed when sick?

11:49am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 Interaction between pt, physician, got to be able to integrate data longitudinally.

11:48am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 Technology and data: all pieces in place (security-wise), amount of data is large but pieces in place...

11:47am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 Is it cost-effective, easy? Tsongalis: grew up with the Jetsons. Wearables too far-fetched?

11:47am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 It's complexity, scale and automation; a defined, cheap device; specific vars or broad assay; run at POC. 'a possibility'

11:45am August 23rd 2018 via Twitter Web Client

Tsongalis #NGDx18 Asks how many think liquid biopsy is disruptive? (More hands) One day: handheld device to detect?… https://t.co/m9Su855FnC

11:43am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 The big change in ID: an immunoassay analyzer built for $3 and a $0.40 disposable, with 50 different strips.

11:41am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 For ID: 'moving from steel to plastic': production equipment dictates pricing (central lab model); n… https://t.co/jXZgF5HfFJ

11:40am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 Make panels for pathologists can do most of the work - if the cost and ease of use concerns are addressed.

11:39am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 Integration of pathologists to the geneticists; talks about simplicity of @pillar_bio - with someone… https://t.co/4jDuIIxLta

11:38am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 New technology like NGS - potentially disruptive when implemented. Pathologists who will talk with treating physicians

11:37am August 23rd 2018 via Twitter Web Client

Scholz #NGDx18 Decentralized is impt for quick decisions, and cost structure. For Cancer: will have limited/no benefit.

11:36am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 Also a 'gateway service' - outsourced sequencing, Getting a workforce trained in genomics impt.

11:35am August 23rd 2018 via Twitter Web Client

Nagarajan #NGDx18 A SaaS business model, a seamless workflow. Assay validation service to help their customers get going.

11:29am August 23rd 2018 via Twitter Web Client

Rakesh Nagarajan (PierianDx) #NGDx18 WashU clinical NGS with inh and cancer, validated clinical testing; spun out in '14

11:28am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 CLIA-cert - for them is so different. They are getting reimbursed "it's hard, one pt was sick for… https://t.co/u55fDQFEqD

11:27am August 23rd 2018 via Twitter Web Client

Icenhour #NGDx18 Helped 800 people so far 'getting help they could not get anywhere'. Told it's impossible for FDA… https://t.co/pBjkiP6QXN

11:25am August 23rd 2018 via Twitter Web Client

Crystal Icenhour (Aperiomics) #NGDx18 They want to 'change everything' about both ID and autoimmune conditions.

11:24am August 23rd 2018 via Twitter Web Client

Scholtz: #NGDx18 With gene sequencing, the issue is at the level of the physician, 'how do I use this info?' Across… https://t.co/xQ1bdb5OvD

11:23am August 23rd 2018 via Twitter Web Client